AMG 925 is primarily investigated for its potential in cancer treatment, particularly in targeting specific pathways involved in tumor growth and survival. It functions as a dual inhibitor of FLT3 and CDK4/6 kinases, which are critical in the regulation of cell cycle and proliferation in certain cancers. This makes it a promising candidate for treating hematologic malignancies, such as acute myeloid leukemia (AML), where FLT3 mutations are commonly observed. By inhibiting these kinases, AMG 925 aims to halt the uncontrolled proliferation of cancer cells and induce apoptosis. Ongoing research focuses on its efficacy, safety, and potential combination with other therapies to enhance treatment outcomes.